Global Leading Market Research Publisher QYResearch announces the release of its latest report “BioPharma Product Testing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global BioPharma Product Testing market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for BioPharma Product Testing was estimated to be worth US$ 9502 million in 2025 and is projected to reach US$ 19150 million, growing at a CAGR of 10.7% from 2026 to 2032.
BioPharma Product Testing refers to the set of laboratory analyses and quality assessments performed on biopharmaceutical products (such as monoclonal antibodies, recombinant proteins, vaccines, cell & gene therapies, and other biologics) to ensure that they are safe, effective, pure, and compliant with regulatory standards before being released to patients.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096605/biopharma-product-testing
1. Industry Pain Points and the Shift Toward Comprehensive Biologic Testing
Biopharmaceutical products—monoclonal antibodies, cell and gene therapies, vaccines, and biosimilars—require rigorous testing to ensure safety, efficacy, purity, and potency. Unlike small-molecule drugs, biologics are large, complex molecules produced in living systems, making them sensitive to manufacturing changes and susceptible to aggregation, degradation, and immunogenicity. BioPharma product testing addresses these challenges through specialized analytical methods (chemical analysis, bioanalysis, stability studies, and purity testing). For drug developers and contract testing organizations, these services are essential for regulatory compliance (FDA, EMA, ICH guidelines), quality control, and biologic safety assurance throughout development and commercialization.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global BioPharma product testing market was valued at US$ 9.502 billion in 2025 and is projected to reach US$ 19.150 billion by 2032, growing at a CAGR of 10.7%. Market growth is driven by three factors: expanding biopharmaceutical pipeline (over 10,000 biologics in development), increasing adoption of biosimilars (requiring extensive comparability studies), and stringent regulatory requirements for cell and gene therapies.
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Cell and gene therapy testing demand: FDA approvals of Kymriah, Zolgensma, and others drove 25% increase in potency and safety testing for viral vectors and CAR-T products.
- Biosimilar comparability studies: European Medicines Agency (EMA) and FDA accelerated biosimilar approvals, requiring extensive analytical similarity testing. Biosimilar segment grew 20% year-over-year.
- Potency assay innovation: New cell-based potency assays (Eurofins, Charles River) for gene therapies reduced testing time from weeks to days.
- Chinese CRO expansion: Pharmaron and Frontage Laboratories increased capacity by 35%, capturing share in Asia-Pacific biologics outsourcing market.
4. Competitive Landscape and Key Suppliers
The market includes global CRO/CDMO giants and specialized bioanalytical laboratories:
- Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek (UK), Thermo Fisher Scientific (US), Charles River Laboratories (US), Labcorp (US), IQVIA (US), ICON plc (Ireland), Syneos Health (US), Pace Analytical (US), Almac Group (UK), BioAgilytix (US), Celerion (US), Frontage Laboratories (China/US), Pharmaron (China), CellCarta (Canada).
Competition centers on three axes: testing capacity (samples/year), regulatory expertise (FDA/EMA), and specialized capabilities (gene therapy, cell-based assays).
5. Segment-by-Segment Analysis: Type and Application
By Test Type
- Bioanalysis: Largest and fastest-growing segment (~55% of market). Pharmacokinetics (PK), immunogenicity (ADA), biomarker analysis, cell-based potency assays. CAGR 12%.
- Chemical Analysis: (~35% of market). Purity (HPLC, CE-SDS), aggregation (SEC), charge variants (iCIEF), peptide mapping (LC-MS).
- Others: Stability testing, sterility, mycoplasma, endotoxin. ~10% of market.
By End User
- Pharmaceutical Research Institute: Largest segment (~80% of market). Biotech and pharma companies outsourcing development and QC testing.
- Hospital: (~15% of market). Hospital laboratories for cell therapy release testing.
- Others: Government, academic. ~5% of market.
User case – Gene therapy potency assay development: A gene therapy company developing AAV-based treatment for hemophilia outsourced potency assay development to Charles River. A cell-based assay (transduction efficiency, functional protein expression) was developed and validated in 6 months, meeting FDA IND requirements. In-house development would have required 12+ months and US$ 2 million.
6. Exclusive Insight: Testing Complexity Across Biologic Modalities
| Modality | Key Testing Challenges | Typical Methods | Cost per Batch |
|---|---|---|---|
| Monoclonal antibody | Aggregation, charge variants, glycosylation | SEC, iCIEF, LC-MS, cell-based potency | US$ 50,000-150,000 |
| Gene therapy (AAV) | Capsid purity, empty/full ratio, potency | SEC-MALS, ddPCR, cell-based transduction | US$ 100,000-300,000 |
| CAR-T cell therapy | Cell viability, transduction efficiency, sterility | Flow cytometry, qPCR, compendial methods | US$ 50,000-100,000 |
| Biosimilar | Analytical similarity (head-to-head) | Extensive panel (30+ methods) | US$ 500,000-2M |
User case – Biosimilar comparability: A biosimilar manufacturer tested its mAb candidate against reference product using Eurofins’ analytical similarity package (40 methods: primary structure, post-translational modifications, purity, potency). The 12-month study met FDA criteria, enabling submission and subsequent approval.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (45% share, CAGR 10.5%). US (Charles River, Labcorp, IQVIA, Thermo Fisher, Syneos, BioAgilytix, Celerion, Pace Analytical). Strong biologics pipeline and CDMO presence.
- Europe: Second-largest (30% share, CAGR 10%). Luxembourg (Eurofins), Switzerland (SGS), UK (Intertek, Almac), Ireland (ICON). Strong regulatory framework.
- Asia-Pacific: Fastest-growing region (CAGR 12.5%). China (Pharmaron, Frontage), India, Japan. Cost-effective CRO services.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The BioPharma product testing market is positioned for strong growth through 2032, driven by biologics pipeline expansion, biosimilar adoption, and cell/gene therapy approvals. Stakeholders—from pharmaceutical companies to CROs—should prioritize cell-based potency assays for gene therapies, analytical similarity packages for biosimilars, and regulatory expertise for global filings. By ensuring quality control and regulatory compliance, BioPharma product testing services are indispensable for biologic drug development and commercialization.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
